NEW YORK (GenomeWeb) – Cynvenio Biosystems said today that it has made Milenia Labs the exclusive distributor of its ClearID Breast Cancer in Mexico.
Cynvenio's ClearID is a blood based assay for treatment selection and monitoring of advanced breast cancer patients. The complany's liquid biopsy technology analyzes circulating tumor cells and circulating cell-free DNA to detect gene alterations that are associated with resistance to a particular treatment. The test is intended for patients undergoing treatment for advanced disease and those who require follow-up testing at regular intervals after completion of therapy.
The agreement makes ClearID Breast Cancer available to customers through Milenia Labs and its network of 12 diagnostic centers in Mexico. Under the terms of the deal, Milenia will also offer Cynvenio’s PD-L1 gene expression reflex assay and other tests as they become commercially available.
Further terms of the agreement were not disclosed.
"Cynvenio's ClearID Breast Cancer test provides an excellent new option for patients based on state-of-the-art liquid biopsy technology that has the benefit of being more affordable compared to other tests in this category," Milenia Labs Director General Salvador Cardona said in a statement.
Cynvenio Chief Commercial Officer Humberto Huerta also noted that this deal is "the cornerstone of our plan to broaden access to ClearID Breast testing services outside the United States."